Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

maculae oedema

- PMLiVE

NICE launches consultation on its methods of drug evaluation

Public consultation launched on Friday 6 November

- PMLiVE

NICE – but not enough

Why evidence is better than assumption when executing commercial strategy

Bayer symbol

Bayer pays an initial $2bn for gene therapy firm AskBio

Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates

- PMLiVE

Bayer’s drop of the future

Digital health isn’t always about digital

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

Impetus Digital Fireside Chat with Tom Hsu, VP, Specialty Medicine at Bayer Canada

Tom Hsu, VP of Specialty Medicine at Bayer Canada,  talks about how he got to where he is today and his experience working for Bayer in China, and how that compares to...

Impetus Digital

Bayer symbol

Bayer gets EU nod for prostate cancer drug Nubeqa

Enters an increasingly competitive market

- PMLiVE

Merck, Bayer flesh out vericiguat heart failure data at ACC

Drug reduced rate of cardiovascular deaths and hospitalisations

Bayer symbol

Bayer signs €250m pact with India’s Curadev for STING drugs

Research will focus on auto-immune and inflammatory diseases

- PMLiVE

NICE looks internally for new chief executive

Deputy chief exec Gillian Leng is set to take the helm

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links